Filtern
Erscheinungsjahr
Dokumenttyp
- Wissenschaftlicher Artikel (51)
- Preprint (1)
Sprache
- Englisch (52)
Volltext vorhanden
- ja (52)
Gehört zur Bibliographie
- nein (52)
Schlagworte
- immunotherapy (4)
- CIK cells (3)
- G-CSF (3)
- hematopoietic stem and progenitor cells (3)
- Apheresis (2)
- BMC (2)
- Bone defect (2)
- CAR (2)
- CXCL12 (2)
- CXCR4 (2)
- Cell therapy (2)
- Mobilization (2)
- Plerixafor (2)
- Stem cell (2)
- allogeneic stem cell transplantation (2)
- cell therapy (2)
- chimeric antigen receptor (2)
- cytokine-induced killer cells (2)
- hematopoiesis (2)
- hematopoietic stem cells (2)
- leukemia (2)
- rhabdomyosarcoma (2)
- stem cell transplantation (2)
- vaccination (2)
- AB-serum (1)
- AMD3100 (1)
- ASCT (1)
- Acute lymphoblastic leukemia (1)
- Allogeneic (1)
- Allogeneic stem cell transplantation (1)
- Anemia management (1)
- Blood loss calculator (1)
- Blood loss formula (1)
- Blood management (1)
- Bone marrow (1)
- Bone marrow mononuclear cells (1)
- Bone regeneration (1)
- CD19 (1)
- CD34 (1)
- CD34+ cell enumeration (1)
- CD34 + cells (1)
- CD49d (1)
- CHIP (1)
- Cancer chemotherapy (1)
- Cancer treatment (1)
- Cell binding (1)
- Cell differentiation (1)
- Cell processing (1)
- Cell-based therapies (1)
- CliniMACS (1)
- Clinical trial (1)
- DNA double-strand break repair (1)
- DSS /AOM (1)
- ERBB2 (1)
- ERBB2 (HER2/neu) (1)
- Engraftment (1)
- Epstein-Barr virus (1)
- Erythropoiesis (1)
- Ewing sarcoma (1)
- Filgrastim (1)
- Flow cytometry (1)
- Gene expression (1)
- Graft (1)
- Graft quality (1)
- HER2/neu (1)
- HSCT (1)
- Healthy stem cell donors (1)
- Hematopoietic stem cell (1)
- IL -17 (1)
- IL -23 (1)
- IL 23p19 knockout mouse (1)
- Immunosuppressive therapy (1)
- Immunotherapy (1)
- Integrins (1)
- Leukemias (1)
- Luciferase (1)
- MMF (1)
- MPA (1)
- MSC-subsets (1)
- MSM (1)
- Machine learning (1)
- Mesenchymal stromal cells (MSC) (1)
- Mouse models (1)
- Multiple sclerosis (1)
- NK-92 (1)
- NSG mice (1)
- Osteonecrosis (1)
- PEM-technology (1)
- Physical and mental health (1)
- Plasmacytoid dendritic cell (1)
- Post-thaw recovery (1)
- Proximal humeral fracture (1)
- Quality control (1)
- RBC (1)
- RBC-depletion (1)
- RMS (1)
- Regeneration (1)
- SARS-CoV-2 (1)
- SARS-CoV-2-specific T cells (1)
- SF-12 (1)
- Second donation (1)
- Sequence motif analysis (1)
- Stem cell dose (1)
- Stem cell enumeration (1)
- Stem cells (1)
- Surgical blood loss (1)
- Transcription factors (1)
- Transcriptional control (1)
- Transplant logistics (1)
- Transplantation (1)
- VLA4 (1)
- Volunteer donor (1)
- Wound healing potential (1)
- acute lymphoblastic leukemia (1)
- acute myeloid leukaemia (1)
- adoptive cancer immunotherapy (1)
- allogeneic (1)
- allogeneic donor (1)
- allogeneic hematological stem cell transplantation (1)
- antibiotic prophylactic therapy (1)
- autoimmune diabetes (1)
- autologous stem cell transplantation (1)
- automation (1)
- blood consumption (1)
- blood safety (1)
- bmal1 (1)
- bone marrow metastasis (1)
- bone metastasis (1)
- breakpoint cluster region (1)
- cancer immunotherapy (1)
- cell motility (1)
- cellular therapy (1)
- charged particles (1)
- chemokine receptor 4 (1)
- chemotherapeutics-treated (1)
- chemotherapy (1)
- children (1)
- chromosomal breaks (1)
- chromosomal integration (1)
- chronic colitis (1)
- circadian rhythm (1)
- clean room (1)
- clock genes (1)
- clonal dominance (1)
- clonal hematopoiesis (1)
- colon cancer (1)
- cortisol (1)
- cryopreservation (1)
- cytotoxic T cells (1)
- donor deferral (1)
- donor recruitment (1)
- donor retention (1)
- donor safety (1)
- epigenetics (1)
- feeder cells (1)
- fresh frozen plasma (1)
- fully human (1)
- gene regulation (1)
- gene therapy (1)
- gene vectors (1)
- good manufacturing practice (1)
- graft-versus host (1)
- granulocytecolony stimulating factor (1)
- haplo-identical (1)
- hematopoietic stem cell mobilization (1)
- hematopoietic stem cell transplantation (1)
- hematopoietic stress (1)
- high-dose chemotherapy (1)
- hospital exemption (1)
- huCAR19 (1)
- immunomagnetic (1)
- induction chemotherapy (1)
- infection precaution (1)
- integrin (1)
- integrins (1)
- lymphoma (1)
- mesenchymal stromal cell (1)
- mobilization (1)
- naked haplo (1)
- natural cytotoxicity (1)
- natural killer cell (1)
- natural killer cells (1)
- nonviral gene delivery (1)
- oncogenes (1)
- p47phox (1)
- patient blood management (1)
- pharmacodynamics (1)
- platelet lysate (1)
- post-transplantation lymphoproliferative disease (1)
- preclinical (1)
- radiation damage response (1)
- radiation-induced leukemia (1)
- refractory aGvHD (1)
- serum albumin deficiency (1)
- sialitis (1)
- somatic mutations (1)
- steroid-resistant aGvHD (1)
- time-lapse imaging (1)
- transcription factors (1)
- transfusion (1)
- transgenically augmented CAR NK cell (1)
- transplantation (1)
- transposition (1)
- type-1-diabetes (1)
Chimeric antigen receptor (CAR) T cells are a novel class of anti-cancer therapy in which autologous or allogeneic T cells are engineered to express a CAR targeting a membrane antigen. In Europe, tisagenlecleucel (Kymriah™) is approved for the treatment of refractory/relapsed acute lymphoblastic leukemia in children and young adults as well as relapsed/refractory diffuse large B-cell lymphoma, while axicabtagene ciloleucel (Yescarta™) is approved for the treatment of relapsed/refractory high-grade B-cell lymphoma and primary mediastinal B-cell lymphoma. Both agents are genetically engineered autologous T cells targeting CD19. These practical recommendations, prepared under the auspices of the European Society of Blood and Marrow Transplantation, relate to patient care and supply chain management under the following headings: patient eligibility, screening laboratory tests and imaging and work-up prior to leukapheresis, how to perform leukapheresis, bridging therapy, lymphodepleting conditioning, product receipt and thawing, infusion of CAR T cells, short-term complications including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, antibiotic prophylaxis, medium-term complications including cytopenias and B-cell aplasia, nursing and psychological support for patients, long-term follow-up, post-authorization safety surveillance, and regulatory issues. These recommendations are not prescriptive and are intended as guidance in the use of this novel therapeutic class.
CXCL12-CXCR4 signaling controls multiple physiological processes and its dysregulation is associated with cancers and inflammatory diseases. To discover as-yet-unknown endogenous ligands of CXCR4, we screened a blood-derived peptide library for inhibitors of CXCR4-tropic HIV-1 strains. This approach identified a 16 amino acid fragment of serum albumin as an effective and highly specific CXCR4 antagonist. The endogenous peptide, termed EPI-X4, is evolutionarily conserved and generated from the highly abundant albumin precursor by pH-regulated proteases. EPI-X4 forms an unusual lasso-like structure and antagonizes CXCL12-induced tumor cell migration, mobilizes stem cells, and suppresses inflammatory responses in mice. Furthermore, the peptide is abundant in the urine of patients with inflammatory kidney diseases and may serve as a biomarker. Our results identify EPI-X4 as a key regulator of CXCR4 signaling and introduce proteolysis of an abundant precursor protein as an alternative concept for chemokine receptor regulation.